G Protein-Coupled Receptor Kinase 2 Selectively Enhances β-Arrestin Recruitment to the D


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
20 10 2023
Historique:
received: 26 09 2023
revised: 16 10 2023
accepted: 18 10 2023
medline: 30 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

The D2 dopamine receptor (D2R) signals through both G proteins and β-arrestins to regulate important physiological processes, such as movement, reward circuitry, emotion, and cognition. β-arrestins are believed to interact with G protein-coupled receptors (GPCRs) at the phosphorylated C-terminal tail or intracellular loops. GPCR kinases (GRKs) are the primary drivers of GPCR phosphorylation, and for many receptors, receptor phosphorylation is indispensable for β-arrestin recruitment. However, GRK-mediated receptor phosphorylation is not required for β-arrestin recruitment to the D2R, and the role of GRKs in D2R-β-arrestin interactions remains largely unexplored. In this study, we used GRK knockout cells engineered using CRISPR-Cas9 technology to determine the extent to which β-arrestin recruitment to the D2R is GRK-dependent. Genetic elimination of all GRK expression decreased, but did not eliminate, agonist-stimulated β-arrestin recruitment to the D2R or its subsequent internalization. However, these processes were rescued upon the re-introduction of various GRK isoforms in the cells with GRK2/3 also enhancing dopamine potency. Further, treatment with compound 101, a pharmacological inhibitor of GRK2/3 isoforms, decreased β-arrestin recruitment and receptor internalization, highlighting the importance of this GRK subfamily for D2R-β-arrestin interactions. These results were recapitulated using a phosphorylation-deficient D2R mutant, emphasizing that GRKs can enhance β-arrestin recruitment and activation independently of receptor phosphorylation.

Identifiants

pubmed: 37892234
pii: biom13101552
doi: 10.3390/biom13101552
pmc: PMC10605370
pii:
doi:

Substances chimiques

Arrestins 0
beta-Arrestins 0
G-Protein-Coupled Receptor Kinases EC 2.7.11.16
Protein Isoforms 0
Receptors, Dopamine 0
Receptors, G-Protein-Coupled 0
GRK2 protein, human EC 2.7.11.15

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Intramural NIH HHS
ID : ZIA NS002263
Pays : United States

Références

Sci Rep. 2012;2:301
pubmed: 22393477
J Biol Chem. 2015 Apr 24;290(17):10775-90
pubmed: 25770216
Sci STKE. 2005 Nov 01;2005(308):cm10
pubmed: 16267056
Pharmacol Ther. 2012 Jan;133(1):40-69
pubmed: 21903131
Nat Protoc. 2010 Sep;5(10):1666-77
pubmed: 20885379
Int J Mol Sci. 2023 Apr 01;24(7):
pubmed: 37047571
J Biol Chem. 2009 Dec 4;284(49):34103-15
pubmed: 19815545
Trends Pharmacol Sci. 2012 Mar;33(3):154-64
pubmed: 22277298
Trends Pharmacol Sci. 1992 Feb;13(2):61-9
pubmed: 1561715
Sci Rep. 2021 Apr 15;11(1):8288
pubmed: 33859231
Neuron. 2003 Apr 24;38(2):291-303
pubmed: 12718862
Pharmacol Rev. 2023 Sep;75(5):854-884
pubmed: 37028945
J Biol Chem. 2018 Apr 20;293(16):6161-6171
pubmed: 29487132
Proc Natl Acad Sci U S A. 2020 Jun 23;117(25):14139-14149
pubmed: 32503917
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3712-7
pubmed: 10097102
J Biol Chem. 2009 May 29;284(22):15038-51
pubmed: 19332542
J Biol Chem. 2007 Apr 6;282(14):10576-84
pubmed: 17283075
Nat Commun. 2022 Jan 27;13(1):540
pubmed: 35087057
Sci Rep. 2020 Oct 15;10(1):17395
pubmed: 33060647
Mol Cell. 2023 Jun 15;83(12):2091-2107.e7
pubmed: 37209686
Curr Opin Cell Biol. 2014 Apr;27:63-71
pubmed: 24680432
Cell Chem Biol. 2023 Apr 20;30(4):362-382.e8
pubmed: 37030291
Nature. 2018 May;557(7705):381-386
pubmed: 29720660
Pharmacol Rev. 2011 Mar;63(1):182-217
pubmed: 21303898
Br J Pharmacol. 2010 Jun;160(4):821-32
pubmed: 20590581
Int J Mol Sci. 2022 Jan 21;23(3):
pubmed: 35163118
Cell Mol Life Sci. 2019 Nov;76(22):4423-4446
pubmed: 31432234
Br J Pharmacol. 2013 Mar;168(6):1355-74
pubmed: 23082996
FASEB J. 2021 Nov;35(11):e22013
pubmed: 34699610
J Biol Chem. 2014 Nov 28;289(48):33663-75
pubmed: 25336643
Elife. 2015 Aug 26;4:
pubmed: 26308580
Nucleic Acids Res. 2018 Jan 4;46(D1):D440-D446
pubmed: 29155946
J Biol Chem. 1994 May 6;269(18):13084-7
pubmed: 8175732
J Biol Chem. 2000 Dec 8;275(49):38213-20
pubmed: 10982802
J Biol Chem. 2001 Oct 5;276(40):37409-14
pubmed: 11473130
Nature. 2016 Mar 31;531(7596):665-8
pubmed: 27007854
J Biol Chem. 2004 Dec 31;279(53):55744-53
pubmed: 15501822
ACS Chem Biol. 2015 Jan 16;10(1):246-56
pubmed: 24984143
Sci Signal. 2020 Feb 04;13(617):
pubmed: 32019899
Nature. 2018 May;557(7705):452-456
pubmed: 29720655
Front Pharmacol. 2019 Feb 19;10:125
pubmed: 30837883
Nat Commun. 2016 Jul 11;7:12178
pubmed: 27397672
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Synapse. 2009 Jul;63(7):621-4
pubmed: 19309759
Mol Pharmacol. 2011 Aug;80(2):294-303
pubmed: 21596927
Nat Commun. 2022 Sep 26;13(1):5638
pubmed: 36163356
Int J Mol Sci. 2023 Apr 04;24(7):
pubmed: 37047716
Pharmacol Res. 2016 Sep;111:1-16
pubmed: 27178731
Cells. 2021 Mar 04;10(3):
pubmed: 33806476
Curr Opin Struct Biol. 2022 Aug;75:102406
pubmed: 35738165
Mol Endocrinol. 2010 Mar;24(3):574-86
pubmed: 20160122
J Biol Chem. 2004 Nov 19;279(47):49533-41
pubmed: 15347675
Mol Cell Endocrinol. 2019 Mar 15;484:34-41
pubmed: 30703488

Auteurs

Marta Sánchez-Soto (M)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Noelia M Boldizsar (NM)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Kayla A Schardien (KA)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Nora S Madaras (NS)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Blair K A Willette (BKA)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Laura R Inbody (LR)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Christopher Dasaro (C)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Amy E Moritz (AE)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Julia Drube (J)

Institut für Molekulare Zellbiologie, CMB-Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Hans-Knöll-Straße 2, D-07745 Jena, Germany.

Raphael S Haider (RS)

Institut für Molekulare Zellbiologie, CMB-Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Hans-Knöll-Straße 2, D-07745 Jena, Germany.
Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK.
Centre of Membrane Protein and Receptors, Universities of Birmingham and Nottingham, Birmingham B15 2TT, UK.

R Benjamin Free (RB)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Carsten Hoffman (C)

Institut für Molekulare Zellbiologie, CMB-Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Hans-Knöll-Straße 2, D-07745 Jena, Germany.

David R Sibley (DR)

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH